Royalty Research Development from 2010 to 2024

RPRX Stock  USD 26.43  0.03  0.11%   
Royalty Pharma Research Development yearly trend continues to be fairly stable with very little volatility. Research Development is likely to outpace its year average in 2024. During the period from 2010 to 2024, Royalty Pharma Research Development regression line of annual values had r-squared of  0.16 and arithmetic mean of  81,309,154. View All Fundamentals
 
Research Development  
First Reported
2000-03-31
Previous Quarter
500 K
Current Value
500 K
Quarterly Volatility
18.6 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 196.5 M, Total Revenue of 2.5 B or Research Development of 57.5 M, as well as many indicators such as Price To Sales Ratio of 5.07, Dividend Yield of 0.0361 or PTB Ratio of 3.83. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.
  
Check out the analysis of Royalty Pharma Correlation against competitors.

Latest Royalty Pharma's Research Development Growth Pattern

Below is the plot of the Research Development of Royalty Pharma Plc over the last few years. It is Royalty Pharma's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Royalty Pharma's overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

Royalty Research Development Regression Statistics

Arithmetic Mean81,309,154
Geometric Mean39,948,972
Coefficient Of Variation129.88
Mean Deviation75,220,698
Median27,107,000
Standard Deviation105,603,286
Sample Variance11152.1T
Range388.1M
R-Value0.40
Mean Square Error10076.2T
R-Squared0.16
Significance0.14
Slope9,475,068
Total Sum of Squares156128.8T

Royalty Research Development History

202457.5 M
202352 M
2022177.1 M
2021200.1 M
202026 M
201983 M
2018392.6 M

About Royalty Pharma Financial Statements

Royalty Pharma investors use historical fundamental indicators, such as Royalty Pharma's Research Development, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Royalty Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Research Development52 M57.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.